Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours Β· Estimated delivery Aug 10 - Aug 15
RCT, Randomized controlled trials
It is designed to be more stable and usable for therapeutic purposes
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
ISO/IEC 17025-Accredited Laboratory Release After lyophilization, each lot is sent to an independent ISO/IEC 17025-accredited laboratory for HPLC purity, mass spectrometry identity, and bacterial endotoxin testing
You're not just boosting GLP-1youre also supporting overall health with compounds to better support an anti-inflammatory response, increased blood sugar control, and improved digestion
US$ 23.61
US$ 19.98
US$ 20.73
US$ 24.50
US$ 20.40
US$ 24.32
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
